Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) Director Claude Nicaise sold 2,491 shares of the firm's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the sale, the director now owns 27,812 shares of the company's stock, valued at $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Sarepta Therapeutics Price Performance
Shares of NASDAQ:SRPT opened at $98.37 on Friday. Sarepta Therapeutics, Inc. has a 12 month low of $97.11 and a 12 month high of $173.25. The stock has a market cap of $9.55 billion, a price-to-earnings ratio of 78.70 and a beta of 0.79. The stock's 50 day moving average price is $112.83 and its 200 day moving average price is $120.55. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its position in Sarepta Therapeutics by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company's stock worth $75,842,000 after buying an additional 12,000 shares during the last quarter. Simplify Asset Management Inc. grew its position in Sarepta Therapeutics by 84.6% in the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company's stock worth $24,105,000 after buying an additional 88,474 shares during the last quarter. Geode Capital Management LLC grew its position in Sarepta Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company's stock worth $211,910,000 after buying an additional 44,306 shares during the last quarter. Summit Partners Public Asset Management LLC grew its position in Sarepta Therapeutics by 547.9% during the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company's stock worth $17,250,000 after purchasing an additional 116,800 shares in the last quarter. Finally, Larson Financial Group LLC grew its position in Sarepta Therapeutics by 1,649.8% during the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company's stock worth $1,093,000 after purchasing an additional 8,249 shares in the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts recently commented on the company. Scotiabank assumed coverage on Sarepta Therapeutics in a research note on Friday, March 7th. They issued a "sector perform" rating and a $105.00 price target for the company. StockNews.com downgraded Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, November 20th. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. Royal Bank of Canada decreased their price target on Sarepta Therapeutics from $165.00 to $161.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Finally, HC Wainwright reiterated a "sell" rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $170.41.
View Our Latest Research Report on Sarepta Therapeutics
About Sarepta Therapeutics
(
Get Free Report)
Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
